Uncategorized
Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has settled litigation with Mati Therapeutics, Inc., regarding alleged infringement of U.S. Patent 7,922,702. Both parties have dismissed all claims and counterclaims against each other in that litigation, which was pending in the United States Dis